Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN).

Full DD Report for BHVN

You must become a subscriber to view this report.


Recent News from (NYSE: BHVN)

Biohaven prices common stock offering
Biohaven Pharmaceutical Holding Company (NYSE: BHVN ) prices its public offering of 3,355,705 common shares at a price of $37.25 per share, for expected gross proceeds of $125M. More news on: Biohaven Pharmaceutical Holding Company Ltd., Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: December, 13 2018 05:59
Biohaven Announces Pricing of Public Offering of Common Shares
NEW HAVEN, Conn. , Dec. 12, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting migraine and neurological diseases, including ...
Source: PR Newswire
Date: December, 12 2018 22:56
Biohaven Pharmaceutical Holding (BHVN) Investor Presentation - Slideshow
The following slide deck was published by Biohaven Pharmaceutical Holding Company Ltd. in conjunction with this Read more ...
Source: SeekingAlpha
Date: December, 11 2018 11:09
Biohaven Announces Proposed Public Offering of Common Shares
NEW HAVEN, Conn. , Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a clinical‑stage biopharmaceutical company with a portfolio of innovative, late‑stage product candidates targeting neurological diseases, including rare disorders, tod...
Source: PR Newswire
Date: December, 10 2018 19:19
Biohaven's rimegepant shows favorable safety profile in long-term migraine study
Initial data from an ongoing long-term, open-label safety study assessing Biohaven Pharmaceutical's ( BHVN -0.6% ) rimegepant for the acute treatment of migraine showed it to be well-tolerated with no liver safety signals in patients receiving once-daily doses for up to one year. Mo...
Source: SeekingAlpha
Date: December, 10 2018 10:18
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
NEW HAVEN, Conn. , Dec. 10, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, ...
Source: PR Newswire
Date: December, 10 2018 03:00
Healthcare and Industrial goods dominate midday movers
More news on: Tesaro, Global Blood Therapeutics, Atossa Genetics, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: December, 03 2018 12:46
Biohaven Pharma up 17% on positive data on migraine med Zydis
Thinly traded Biohaven Pharmaceutical Holding Company ( BHVN +17.1% ) is up on more than double normal volume following its announcement of topline data from a Phase 3 clinical trial, BHV3000-303 , evaluating lead candidate Zydis (rimegepant) orally dissolving tablet for the acute treat...
Source: SeekingAlpha
Date: December, 03 2018 12:05
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
NEW HAVEN, Conn. , Dec. 3, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy and safety of its Zydis ® oral...
Source: PR Newswire
Date: December, 03 2018 03:00
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Deals and Financings BeiGene (BGNE) (HKEX:06160) of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks (ZYME) (see story ). BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispe...
Source: SeekingAlpha
Date: December, 02 2018 10:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0835.2135.5036.2934.75145,911
2018-05-1729.87530.2930.7429.41312,372

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-143,2898,73637.6488Short
2018-12-1322,08639,36056.1128Short
2018-12-122,0297,09528.5976Cover
2018-12-115,20823,78321.8980Cover
2018-12-106,68577,8478.5874Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BHVN.


About Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)

Logo for Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NYSE: BHVN)

      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 16 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 15 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 11 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 05 2018
      General form for registration of securities under the Securities Act of 1933
      Filing Type: S-1Filing Source: edgar
      Filing Date: April, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 29 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 09 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NYSE: BHVN)

      Daily Technical Chart for (NYSE: BHVN)


      Stay tuned for daily updates and more on (NYSE: BHVN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NYSE: BHVN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BHVN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BHVN and does not buy, sell, or trade any shares of BHVN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/